

• **Name:** Annette Sunhi Kim, MD, PhD

• **Current Position:**

- Associate Professor, Department of Pathology, Harvard Medical School, Boston, MA
- Associate Pathologist, Department of Pathology, Division of Hematopathology, Brigham and Women's Hospital, Boston, MA
- Assistant Director, Center of Advanced Molecular Diagnostics, Department of Pathology, Brigham and Women's Hospital, Boston, MA

• **Country:** United States

• **Educational Background:**

1987-1991	A.B. (<i>Summa cum Laude</i>)	Chemistry	Harvard University
1991-1998	M.D.	Medical Doctor	Harvard Medical School
1991-1998	Ph.D.	Organic Chemistry	Harvard University
1998-2000	Post-doctoral fellow	NMR Structural biology	Memorial Sloan Kettering Cancer Center
2004-2006	Resident	Clinical Pathology	University of Pennsylvania
2006-2007	Fellow	Hematopathology	University of Pennsylvania
2007-2008	Resident	Clinical Pathology	University of Pennsylvania

• **Professional Experiences:**

2000-2002	Research Fellow	Medicinal Chemistry	Merck Research Laboratories
2002-2003	Project Lead	Cancer Biology	Merck Research Laboratories
2008-2009	Associate Professor	Pathology	University of Medicine and Dentistry, New Jersey
2008-2009	Medical Director of the Clinical Laboratories	Pathology	Cooper University Hospital

2009-2015	Assistant Professor	Pathology	Vanderbilt University
2010-2015	Associate Director of Molecular Diagnostic Laboratory	Pathology	Vanderbilt University
2013-2015	Staff Hematopathologist	Pathology	Tennessee Valley Healthcare System, VA

• Professional Organizations

1990 -	American Chemical Society
1993-	Massachusetts Medical Society
1993-2000	American Medical Society
2007-	College of American Pathologists
2014-2020	Member, Molecular Oncology Committee
2008-	American Society of Clinical Pathologists
2008-	Association of Molecular Pathology
2011-2013	Member, Training and Education Committee
2011-2015	Hematopathology Subdivision Leadership
2013-2015	Member, Clinical Practice Committee
2014	AMP Representative to the ASCO Genomics Roundtable
2014-	AMP Representative to the Exploratory Guidelines Working Group
2015-	Member, MDS/MPN Working Group
2015-2017	Chair, Training and Education Committee
2015-2017	Board Member
2010-	American Society of Hematology
2010-	Eastern Cooperative Oncology Group
2011-	Children's Oncology Group
2012-	United States and Canadian Academy of Pathology
2016-	Society of Hematopathology



•Main Scientific Publications

(selection since 2000, **first author or primary author status**):

1. **Kim, A.S.**, Kakalis, L., Abdul-Manan, N., Liu, G.A., and Rosen, M.K. Autoinhibition and Activation Mechanisms of the Wiskott-Aldrich Syndrome Protein, a Cdc42 Effector. *Nature* 2000;404:151-158.
2. Devriendt, K., **Kim, A.S.**, Mathijs, G., Frints, S.G.M., Schwartz, M., Van den Oord, J.J., Verhoef, G.E.G., Boogaerts, M.A., Fryns, J.-P., You, D., Rosen, M.K., and Vandenberghe, P. Constitutively Activating Mutation in WASP Causes X-Linked Severe Congenital Neutropenia. *Nature Genetics* 2001;27:313-317.
3. Peterson, J.R., Bickford, L.C., Morgan, D., **Kim, A.S.**, Ouerfelli, O., Kirshner, M.W., and Rosen, M.K. Chemical Inhibition of N-WASP by Stabilization of a Native Autoinhibited Conformation. *Nature Structural and Molecular Biology* 2004;11:747-755.
4. *****Kim, A. S.** "Clinical Impact of Gene Expression Profiling on Oncology Diagnosis, Prognosis, and Treatment" *Combinatorial Chemistry and High Throughput Screening* 7, 183-206 (2004). (***)Invited submission)
5. Bell, I., Stirdivant, S. M., Ahern, J., Culberson, J. C., Darke, P. L., Dinsmore, C. J., Drakas, R.A., Gallicchio, S.N., Graham, S. L., Heimbrook, D.C., Hall, D.L., Hua, J., Kett, N.R., **Kim, A. S.**, Kornienko, M., Kuo, L.C., Munshi, S.K., Quigley, A. G., Reid, J.C., Trotter, B.W., Waxman, L.H., Williams, T.M., and Zartman, C.B. Biochemical and Structural Characterization of a Novel Class of Inhibitors of the Type I Insulin-Like Growth Factor Receptor Kinase. *Biochemistry* 2005;44:9430-9440.
6. **Kim, A.S.**, Luger, S., Van Deerlin, V.M., Goldstein, S., and Bagg, A. Sudden extramedullary T-lymphoblastic blast crisis in chronic myelogenous leukemia: a non-random event associated with imatinib? *American Journal of Clinical Pathology* 2008;129:639-648.
7. **Kim, A.S.**, Cook, R., Wainwright, L.M., Biegel, J.A., Schuster, S.J., and Wasik, M. A. Dramatic response of acute monoblastic leukemia induced by a single dose of taxotere." *Leukemia and Lymphoma* 2008;49:577-580.
8. Ma, L., Katz, Y., Sharan, K., **Kim, A.S.** EBV-Associated Anaplastic Large Cell Lymphoma: Myth or Reality. *Int. J. of Clin. Exp. Pathol.* 2010;20:100-110.